Akari Therapeutics shares surge 13.34% after-hours after appointing Kameel Farag as interim CFO, citing his biotech finance expertise and capital-raising track record.

Akari Therapeutics surged 13.34% in after-hours trading following the announcement of Kameel D. Farag’s appointment as Interim Chief Financial Officer. Farag, a biotech finance executive with over two decades of experience, has led companies through transformative growth, including securing $150M+ in financing and scaling operations at Aspen Neuroscience and Ionis Pharmaceuticals. His expertise in capital raising and operational strategy aligns with Akari’s focus on advancing its novel ADC platform and lead asset, AKTX-101, toward clinical trials. The hiring signals strengthened leadership amid the company’s efforts to accelerate pipeline development, bolstering investor confidence in its ability to execute growth initiatives and secure funding for preclinical-to-clinical transitions. The move underscores strategic credibility for the micro-cap biotech, which faces pressure to deliver milestones in its oncology-focused ADC development.